The CREPE Score: A Predictive Tool for Third-Generation Cephalosporin-Resistant Enterobacterales Pneumonia in Community Settings

References

• Assefa M. Multi-drug resistant gram-negative bacterial pneumonia: etiology, risk factors, and drug resistance patterns. Pneumonia. 2022;14:4.
   Web of Science ®Google Scholar
• Kuti EL, Patel AA, Coleman CI. Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and blood stream infection: a meta-analysis. J Crit Care. 2008;23(1):91–100.
   PubMed Web of Science ®Google Scholar
• Rhee C, Kadri SS, Dekker JP, et al. Prevalence of antibiotic-resistant pathogens in culture-proven sepsis and outcomes associated with inadequate and broad-spectrum empiric antibiotic use. JAMA Netw Open. 2020;3(4):e202899.
   PubMed Web of Science ®Google Scholar
• Niederman MS. Hospital-acquired pneumonia, health care-associated pneumonia, ventilator-associated pneumonia, and ventilator-associated tracheobronchitis: definitions and challenges in trial design. Clin Infect Dis. 2010;51(Suppl 1):S12–7.
   PubMedGoogle Scholar
• Ewig S, Kolditz M, Pletz MW, et al. Healthcare-associated pneumonia: is there any reason to continue to utilize this label in 2019? Clin Microbiol Infect. 2019;25(10):1173–1179.
   PubMed Web of Science ®Google Scholar
• Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia: an official clinical practice guideline of the American thoracic society and infectious diseases society of America. Am J Respir Crit Care Med. 2019;200(7):e45–67.
   PubMed Web of Science ®Google Scholar
• von Baum H, Welte T, Marre R, et al. Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors. Eur Respir J. 2010;35(3):598–605.
   PubMed Web of Science ®Google Scholar
• Villafuerte D, Aliberti S, Soni NJ, et al. Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community-acquired pneumonia. Respirol Carlton Vic. 2020;25(5):543–551.
   PubMed Web of Science ®Google Scholar
• Luan Y, Sun Y, Duan S, et al. Pathogenic bacterial profile and drug resistance analysis of community-acquired pneumonia in older outpatients with fever. J Int Med Res. 2018;46(11):4596–4604.
   PubMed Web of Science ®Google Scholar
• Peto L, Nadjm B, Horby P, et al. The bacterial aetiology of adult community-acquired pneumonia in Asia: a systematic review. Trans R Soc Trop Med Hyg. 2014;108(6):326–337.
   PubMed Web of Science ®Google Scholar
• Tran HD, Bach Nguyen YT, Thanh Tran T, et al. Community-acquired pneumonia-causing bacteria and antibiotic resistance rate among Vietnamese patients: a cross-sectional study. Medicine. 2022;101(36):e30458.
   PubMed Web of Science ®Google Scholar
• Qu J, Zhang J, Chen Y, et al. Aetiology of severe community acquired pneumonia in adults identified by combined detection methods: a multi-centre prospective study in China. Emerg Microbes Infect. 2022;11(1):556–566.
   PubMed Web of Science ®Google Scholar
• Olsen SJ, Laosiritaworn Y, Siasiriwattana S, et al. The incidence of pneumonia in rural Thailand. Int J Infect Dis. 2006;10(6):439–445.
   PubMed Web of Science ®Google Scholar
• Bjarnason A, Westin J, Lindh M, et al. Incidence, etiology, and outcomes of community-acquired pneumonia: a population-based study. Open Forum Infect Dis. 2018;5(2):ofy010.
   PubMed Web of Science ®Google Scholar
• Mekviwattanawong S, Srifuengfung S, Chokepaibulkit K, et al. Epidemiology of Staphylococcus aureus infections and the prevalence of infection caused by community-acquired methicillin-resistant Staphylococcus aureus in hospitalized patients at Siriraj Hospital. J Med Assoc Thai. 2006;89(Suppl 5):S106–117.
   PubMedGoogle Scholar
• Restrepo MI, Babu BL, Reyes LF, et al. Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients. Eur Respir J. 2018;52:1701190.
   PubMed Web of Science ®Google Scholar
• Aston SJ, Wootton DG. Community-acquired pneumonia due to drug-resistant Enterobacteriaceae: a global perspective. Respirology. 2020;25(5):468–469.
   PubMed Web of Science ®Google Scholar
• Maruyama T, Fujisawa T, Ishida T, et al. A therapeutic strategy for all pneumonia patients: a 3-year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy. Clin Infect Dis. 2019;68(7):1080–1088.
   PubMed Web of Science ®Google Scholar
• Klein NC, Cunha BA. Third-generation cephalosporins. Med Clin North Am. 1995;79(4):705–719.
   PubMed Web of Science ®Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281.
   PubMed Web of Science ®Google Scholar
• Fraser A, Paul M, Almanasreh N, et al. Benefit of appropriate empirical antibiotic treatment: thirty-day mortality and duration of hospital stay. Am J Med. 2006;119(11):970–976.
   PubMed Web of Science ®Google Scholar
• Mettler J, Simcock M, Sendi P, et al. Empirical use of antibiotics and adjustment of empirical antibiotic therapies in a university hospital: a prospective observational study. BMC Infect Dis. 2007;7:21.
   PubMed Web of Science ®Google Scholar
• Cillóniz C, Dominedò C, Torres A. Multidrug resistant gram-negative bacteria in community-acquired pneumonia. Crit Care. 2019;23:79.
   PubMed Web of Science ®Google Scholar
• Dever LA, Dermody TS. Mechanisms of bacterial resistance to antibiotics. Arch Intern Med. 1991;151(5):886–895.
   PubMedGoogle Scholar
• Madaras-Kelly KJ, Remington RE, Fan VS, et al. Predicting antibiotic resistance to community-acquired pneumonia antibiotics in culture-positive patients with healthcare-associated pneumonia. J Hosp Med. 2012;7(3):195–202.
   PubMed Web of Science ®Google Scholar
• Shindo Y, Ito R, Kobayashi D, et al. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2013;188(8):985–995.
   PubMed Web of Science ®Google Scholar
• Baljin B, Gurjav U, Tulgaa K, et al. High acquisition rate of gram-negative multi-drug resistant organism colonization during hospitalization: a perspective from a high endemic setting. Infect Drug Resist. 2021;14:3919–3927.
   PubMed Web of Science ®Google Scholar
• Ramirez JA, Musher DM, Evans SE, et al. Treatment of community-acquired pneumonia in immunocompromised adults. Chest. 2020;158(5):1896–1911.
   PubMed Web of Science ®Google Scholar
• Fadrian F, Chen K, Kumalawati J, et al. The validation of drug resistance in pneumonia (DRIP) score in predicting infections due to drug-resistant pathogens in community-acquired pneumonia at Cipto Mangunkusumo Hospital, Jakarta, Indonesia. Acta Medica Indones. 2021;53(4):416–422.
   PubMed Web of Science ®Google Scholar
• Shorr AF, Myers DE, Huang DB, et al. A risk score for identifying methicillin-resistant Staphylococcus aureus in patients presenting to the hospital with pneumonia. BMC Infect Dis. 2013;13:268.
   PubMed Web of Science ®Google Scholar
• Prina E, Ranzani OT, Polverino E, et al. Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. Ann Am Thorac Soc. 2015;12(2):153–160.
   PubMed Web of Science ®Google Scholar
• Ceccato A, Mendez R, Ewig S, et al. Validation of a Prediction Score for Drug-Resistant Microorganisms in Community-acquired Pneumonia. Ann Am Thorac Soc. 2021;18(2):257–265.
   PubMed Web of Science ®Google Scholar
• Oliver MB, Fong K, Certain L, et al. Validation of a community-acquired pneumonia score to improve empiric antibiotic selection at an academic medical center. Antimicrob Agents Chemother. 2021;65(2):e01482–20.
   PubMed Web of Science ®Google Scholar